Am80, a retinoic acid receptor agonist, activates the cardiomyocyte cell cycle and enhances engraftment in the heart

Stem Cell Reports. 2023 Aug 8;18(8):1672-1685. doi: 10.1016/j.stemcr.2023.06.006. Epub 2023 Jul 13.

Abstract

Human induced pluripotent stem cell-derived (hiPSC) cardiomyocytes are a promising source for regenerative therapy. To realize this therapy, however, their engraftment potential after their injection into the host heart should be improved. Here, we established an efficient method to analyze the cell cycle activity of hiPSC cardiomyocytes using a fluorescence ubiquitination-based cell cycle indicator (FUCCI) system. In vitro high-throughput screening using FUCCI identified a retinoic acid receptor (RAR) agonist, Am80, as an effective cell cycle activator in hiPSC cardiomyocytes. The transplantation of hiPSC cardiomyocytes treated with Am80 before the injection significantly enhanced the engraftment in damaged mouse heart for 6 months. Finally, we revealed that the activation of endogenous Wnt pathways through both RARA and RARB underlies the Am80-mediated cell cycle activation. Collectively, this study highlights an efficient method to activate cell cycle in hiPSC cardiomyocytes by Am80 as a means to increase the graft size after cell transplantation into a damaged heart.

Keywords: Cardiac cell transplantation; Cell cycle; FUCCI; cardiomyocyte differentiation; high throughput screening; human induced pluripotent stem cells; retinoic acid.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cell Cycle
  • Cell Differentiation
  • Humans
  • Induced Pluripotent Stem Cells* / metabolism
  • Mice
  • Myocytes, Cardiac*
  • Receptors, Retinoic Acid / metabolism

Substances

  • tamibarotene
  • Receptors, Retinoic Acid